文献速递其他结缔组织病

利妥昔单抗治疗系统性硬化相关间质性肺病的多中心开放标签对照研究

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
PubMed 文献 · Semin Arthritis Rheum · 2016-10-13

该多中心开放标签对照研究纳入51例系统性硬化相关间质性肺病患者,分别接受利妥昔单抗(RTX,n=33)或常规治疗(n=18),中位随访4年。结果显示RTX组2年时FVC较基线显著升高,而对照组无变化;7年时RTX组FVC仍高于基线,对照组恶化,组间比较RTX组FVC获益显著。皮肤增厚改善两组均见,但RTX组在所有时间点均更优,不良事件两组相当。

要点

  • RTX组2年FVC较基线显著升高(80.60±21.21 vs 86.90±20.56,p=0.041),对照组无变化。
  • 7年时RTX组FVC仍高于基线,对照组恶化,组间比较RTX组FVC获益显著(p=0.013)。
  • 皮肤增厚改善两组均见,但RTX组在所有时间点均更优,不良事件两组相当。

核心结论

  • RTX对系统性硬化相关间质性肺病患者的肺功能和皮肤纤维化具有有益作用。
  • 仍需开展随机对照研究进一步验证。

研究设计与样本

  • 多中心、开放标签、对照研究,共纳入51例系统性硬化相关间质性肺病患者。
  • RTX组33例,常规治疗组18例,常规治疗包括硫唑嘌呤(n=2)、甲氨蝶呤(n=6)和霉酚酸酯(n=10)。
  • 中位随访4年(范围1-7年)。

主要发现

  • RTX组2年时FVC较基线显著升高(均值±SD:80.60±21.21 vs 86.90±20.56,p=0.041),对照组前2年FVC无变化。
  • 7年时RTX组剩余5例FVC仍高于基线(均值±SD:91.60±14.81,p=0.158),对照组剩余9例FVC恶化(p<0.01)。
  • 两组直接比较显示RTX组FVC获益显著(p=0.013)。
  • 皮肤增厚改善两组均见,但组间直接比较在所有时间点均强烈 favoring RTX。
  • 不良事件两组相当。

关键数值与推荐

  • RTX组2年FVC较基线升高,p=0.041。
  • 7年时RTX组FVC较基线p=0.158,对照组FVC较基线p<0.01。
  • 两组FVC直接比较p=0.013。

临床怎么用

  • 对于系统性硬化相关间质性肺病患者,RTX可能改善肺功能并延缓FVC下降。
  • RTX可能对皮肤纤维化有额外获益,且不良事件与常规治疗相当。

局限性

  • 研究为开放标签设计,非随机对照。
  • 样本量较小,7年时RTX组仅剩5例、对照组仅剩9例。
  • 常规治疗组药物异质,包括硫唑嘌呤、甲氨蝶呤和霉酚酸酯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in SSc compared to standard treatment. METHODS: A total of 51 patients with SSc-associated interstitial lung disease were recruited and treated with RTX (n = 33) or conventional treatment (n = 18). Median follow-up was 4 years (range: 1-7). Conventional treatment consisted of azathioprine (n = 2), methotrexate (n = 6), and mycophenolate mofetil (n = 10). RESULTS: Patients in the RTX group showed an increase in FVC at 2 years (mean ± SD of FVC: 80.60 ± 21.21 vs 86.90 ± 20.56 at baseline vs 2 years, respectively, p = 0.041 compared to baseline). In sharp contrast, patients in the control group had no change in FVC during the first 2 years of follow-up. At the 7 year time point the remaining patients in the RTX group (n = 5) had higher FVC compared to baseline (mean ± SD of FVC: 91.60 ± 14.81, p = 0.158 compared to baseline) in contrast to patients in the control group (n = 9) where FVC deteriorated (p < 0.01, compared to baseline). Direct comparison between the 2 groups showed a significant benefit for the RTX group in FVC (p = 0.013). Improvement of skin thickening was found in both the RTX and the standard treatment group; however, direct comparison between groups strongly favored RTX at all-time points. Adverse events were comparable between groups. CONCLUSIONS: Our data indicate that RTX has a beneficial effect on lung function and skin fibrosis in patients with SSc. Randomized controlled studies are highly needed.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2016. PMID: 27839742. doi:10.1016/j.semarthrit.2016.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。